Adenocyte

Company Overview

Snapshot

Founded in December 2020 by Mark Rutenberg, Adenocyte operates with 1–10 employees. The company has secured funding across one round from one investor. In May 2026, Adenocyte received an investment from iGan Partners.

Business overview

Adenocyte is a Health Tech & Life Sciences company focused on improving early cancer detection. The company develops LINFU, a low-intensity non-focused ultrasound method designed to enhance cytology sample quality in cancer screening. This technology utilizes brief extracorporeal ultrasound exposure with microbubble contrast to increase the exfoliation of pancreatic ductal cells into pancreatic fluid, thereby creating richer cytology specimens for laboratory analysis. Adenocyte's initial application targets gastroenterologists, cytopathology labs, pancreatic cancer screening programs, and clinicians managing high-risk patients, with the aim of detecting pancreatic dysplasia and early pancreatic ductal adenocarcinoma when intervention can be most effective. The company operates within the Pharma & Medical Biotechnology and Medical Devices sectors, specifically focusing on Test Diagnostics & Screening and Diagnostics Devices.

Strategic signal

In May 2026, Adenocyte received an investment from iGan Partners. This funding signals investor confidence in Adenocyte's LINFU technology and its potential to significantly advance early pancreatic cancer detection. For investors, this indicates a positive trajectory for the company's clinical development and market entry in the high-impact field of oncology diagnostics.

Company Intelligence Q&A

What is Adenocyte's core technology?

Adenocyte develops LINFU, a low-intensity non-focused ultrasound method that improves cytology sample quality in cancer screening by increasing the exfoliation of pancreatic ductal cells into pancreatic fluid for richer specimens.

When was Adenocyte founded and by whom?

Adenocyte was founded in December 2020 by Mark Rutenberg.

Who invested in Adenocyte in May 2026?

In May 2026, Adenocyte received an investment from iGan Partners.

What markets does Adenocyte's technology target?

Adenocyte's LINFU technology targets gastroenterologists, cytopathology labs, pancreatic cancer screening programs, and clinicians managing high-risk patients for early detection of pancreatic dysplasia and adenocarcinoma.

What is the current product stage of Adenocyte's technology?

Adenocyte's LINFU technology is currently in the Clinical Trial stage, as of May 2026, aiming to enhance cytology sample quality for earlier pancreatic cancer detection.